Concepedia

M. A. Stroehlein

MA

Statistics

Publications

4

Citations

56

H-Index

4

Active since

2004

Affiliations

Neovii Biotech (Germany)(Current)

M. A. Stroehlein is an author at Neovii Biotech (Germany) specializing in oncology, medicine, and malignant ascites.

Publications per year

2004–2008

4

Publications

4

Intraperitoneal treatment of malignant ascites due to epithelial tumors with catumaxomab: A phase II/III study

S. Parsons, P. Murawa, P. Koralewski et al. · Journal of Clinical Oncology · 2008 · 21 citations

Medicine, Oncology, Gastrointestinal Oncology +1

Treatment of ovarian cancer patients with malignant ascites using the trifunctional antibody catumaxomab: Results of a phase II/III study

SL Parsons, E. Kutarska, P. Koralewski et al. · Journal of Clinical Oncology · 2007 · 15 citations

Medicine, Oncology, Pharmacotherapy +17

Immunotherapy with the trifunctional antibody removab leads to significant elimination of tumor cells from malignant ascites in ovarian cancer: Results of a phase I/II study

Markus Jaeger, M. A. Stroehlein, A. Schoberth et al. · Journal of Clinical Oncology · 2004 · 10 citations

Life Sciences, Immunology, Oncology +17

Efficacy of intraperitoneal treatment with the trifunctional antibody catumaxomab in patients with GI-tract cancer and peritoneal carcinomatosis: A matched-pair analysis

M. A. Stroehlein, K. U. Gruetzner, Anwar Tarabichi et al. · Journal of Clinical Oncology · 2006 · 10 citations

Medicine, Oncology, Pharmacology +15

1–4 of 4